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Abstract: This study examines the value of a goat cheese naturally enriched in polyunsaturated fatty
acids (PUFA) (n-3 PUFA and conjugated linolenic acid (CLA)) as means of improving cardiovascular
and inflammatory health. Sixty-eight overweight and obese subjects (BMI ≥ 27 and <40 kg/m2), with
at least two risk factors for cardiovascular disease (CVD) in a lipid panel blood tests, participated in
a randomized, placebo-controlled, double-blind, parallel designed study. The subjects consumed
for 12 weeks: (1) 60 g/d control goat cheese and (2) 60 g/d goat cheese naturally enriched in n-3
PUFA and CLA. Diet and physical activity were assessed. Anthropometric and dual-energy X-ray
absorptiometry (DXA) tests were performed. Blood samples were collected at the beginning and
at the end of the study period. Changes in health status, lifestyle and dietary habits, and daily
compliance were recorded. The consumption of a PUFA-enriched goat cheese significantly increased
plasma high-density lipoprotein (HDL)-cholesterol, as well as in apolipoprotein B, and it significantly
decreased high-sensitivity C-reactive protein concentrations compared to the control goat cheese
(p < 0.05). The significant improvement of the plasma lipid profile and inflammatory status of people
with risk for CVD due to the consumption of PUFA-enriched cheese suggests a potential role of this
dairy product as an alternative to develop high nutritional value food in a balanced diet comprising
regular exercise.
Keywords: n-3 PUFA; CLA; cheese; blood lipids; dairy fat
1. Introduction
Cardiovascular disease (CVD) is the leading cause of death worldwide. The major risk factors
are well-established and are mediated mainly by hypertension, dyslipidemia, and smoking, as well
as others such as obesity, elevated cholesterol, poor diet, and physical activity. Due to the significant
influence exerted by diet and lifestyle, the current nutritional recommendations like controlling the
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amount and quality and quality of the fats consumed in the diet and salt intake, as well as regular
physical exercise, are key to the prevention and treatment of CVD [1].
Within this framework, the effect of polyunsaturated fatty acids (PUFA), such as α-linolenic acid
(ALA) n-3, has been demonstrated through mechanisms involving anti-inflammatory, anti-arrhythmic,
and anti-thrombotic properties, which reduce low-density lipoprotein cholesterol levels (LDL-C) and,
to a lesser extent, high-density lipoprotein cholesterol levels (HDL-C) when they replace saturated
fatty acids (SFA) [2]. Even though these beneficial effects are well known, in the last 100 years, the
dietary ratio of n-6/n-3 PUFA in modern Western diets has dramatically increased to 15-17:1, which
has been associated with an increase of many other illnesses including inflammatory diseases and
cholesterolaemia [3]. In addition, some clinical trials in humans have indicated that conjugated linolenic
acid (CLA) may have several beneficial effects for health, such as improving the blood lipid profile
related to CVD and diabetes [4]. However, it is important to know the exact dose of CLA and the
duration of the treatment to know the biological effects [4].
In recent decades, a wide variety of functional foods have been designed to reduce some of the
factors that induce cardiovascular risks and to improve health [5]. Thus, one possible way to increase
PUFA consumption is to enrich foods that are regularly consumed by the majority of the population
such as dairy products. Even though full fat dairy products consumption has long been considered
a risk factor for cardiovascular health, such products contribute to the mean daily intakes of energy
(11%), protein (14%), fat (17%), calcium (48%), phosphorous (24%), and vitamin A (27%). Though
further studies are needed, a recent meta-analysis has demonstrated that dairy product consumption is
not associated with CVD [6]. Some studies have even proposed a distinction between dairy and other
food sources of SFA based on their different effects on blood lipids [7] and the possible cardioprotective
effect of eating fermented dairy products [8].
Modulating milk FA composition through the ruminant feeding, particularly with oilseeds rich in
PUFA, has shown to be a valuable tool to improve milk nutritional value [9]. In particular, goat´s milk
possesses some inherent properties and a great nutritional quality determined by its lipid composition,
which makes it an attractive alternative to developing dairy products with a high added value, like
cheese. In this respect, our group developed and characterized a goat cheese naturally enriched in CLA
and omega-3 [9] to be further employed in a clinical trial on cardiovascular risk prevention in humans.
Thus, a randomized controlled trial was performed in order to assess the effect of the consumption
of that PUFA-enriched cheese in modulating blood lipids (total cholesterol (TC), HDL-C, LDL-C,
triglycerides (TAG), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and free fatty acids (FFA),
as well as other cardiovascular risk factors, such as inflammatory markers, in overweight and
obese subjects.
2. Materials and Methods
The present study was registered at http://clinicaltrials.gov under the number NCT02630602.
2.1. Subjects
For the present study, the Clinical Nutrition Department of La Paz University Hospital (HULP) in
Madrid (Spain) recruited 68 overweight and obese subjects (52 women and 16 men) between January
and March 2014. The inclusion criteria were: aged 18–65 years living in the region of Madrid, Spain;
body mass index (BMI) ≥ 27 < 40 Kg/m2; to have a CVD risk score < 10% [10]; at least two atherogenic
risk factors: TAG ≥ 150 mg/dL and <200 mg/dL, TC ≥ 200 mg/dL, HDL-C <40 mg/dL men or <50 mg/dL
women, and/or LDL-C ≥130 mg/dL and <160 mg/dL, reflecting a risk for CVD [10]; having a suitable
understanding of the clinical trial level; agreeing to voluntarily participate in the study; and signing
the informed consent. Exclusion criteria were a diagnosis of diabetes mellitus, chronic degenerative
diseases (e.g., liver or kidney), dyslipidemia, mental illness or diminished cognitive function, or the
taking of antihypertension or lipid-lowering medication (e.g., statins, omega-3 supplements). Persons
with lactose intolerance and dairy protein allergies were not enrolled. Pregnant or breastfeeding
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women were also excluded. The participants were individually allocated to one of the two study
groups by randomization (Figure 1).
In addition, all groups followed the same balanced hypocaloric diet. All subjects gave their
informed consent to take part in the study, which was approved by The Scientific Research and Ethics
Committee of the Hospital Universitario La Paz (HULP 4092) and conformed to the ethical standards
of the Declaration of Helsinki [11]; authorization for the disclosure of protected health information
was obtained from all subjects before protocol-specific procedures. The participants were individually
allocated to one of the two study groups, generated by a randomization procedure provided by the
Biostatistics Unit of La Paz University Hospital. The allocation ratio of the study groups was 1:1.
2.2. Study Design
The controlled, randomized, double blind, parallel dietary intervention trial consisted of a 12-week
investigation period (84 days). The control group (CG) received 60 g/day of a commercial goat cheese,
and the experimental group (EG) received 60 g/day of the goat cheese that was naturally enriched with
n-3 PUFA and CLA. Both control and enriched cheeses were produced as described by Santurino et al.
(2017) [12]. Immediately after manufacture, the control and enriched cheeses were vacuum packed,
refrigerated, and marked to maintain the conditions of blinding. Thus, neither the participants nor the
researchers knew to which group the members belonged until the end of the study.
2.3. Dietetic, Physical Activity and Comorbidities’ Data
Balanced hypocaloric and personalized diets were individually prescribed for all participants.
An energy restriction of approximately 400 kcal/day was prescribed depending on gender, age, BMI,
nutritional habits, physical activity, comorbidities and previous dietary treatments. Dietary intake was
recorded using a food frequency questionnaire and a “3-day food and drink record” validated for the
Spanish population [13] for computing energy, fat and protein intake. Two weekdays and one weekend
day were included in the dietary record to take any differences in nutrient intake during weekdays
and weekends into account. This was achieved by guidance from our dietitian. Subjects attended the
department to collect the test food and for follow-up every three weeks throughout the intervention
period. A questionnaire was fulfilled to collect the current use of medications and supplements, and
the presence of relevant previous diseases and a physical activity metabolic equivalent of task (MET)
score was determined based on self-reported energy-consuming activities during work, at home, while
travelling, and at leisure time based on “Global Recommendations on Physical Activity for Health” by
the WHO.
2.4. Anthropometric Variables
Blood pressure and heart rate were measured three times at 5-min intervals on the right arm
using a Welch automatic monitor (Allyn Spot Vital Signs 420 series, Amsterdam, The Netherlands)
(accuracy ±5 mmHg). The measurements were taken with subjects sitting, and the means were
calculated. Dual-energy X-ray absorptiometry (DXA) was used to measure the total fat mass (TFM (%)),
bone mineral density (BMD (g/cm2)), android fat (AF (%)), gynoid (GF), and the lean mass (LM (%)),
employing a GE Lunar Prodigy apparatus (GE Healthcare, Madison, WI, USA). Finally, anthropometric
measurements as subject composition (TANITA BC-420MA, Biológica Tecnología Médica S.L. Barcelona,
Spain), BMI, and waist and hip circumference were measured and recorded while adhering to
international norms set out by the WHO.
2.5. Blood Collection
Blood samples were taken at baseline and at the end of the study period after a 12 h overnight fast
at the Extraction Unit of the Hospital Universitario La Paz (Madrid, Spain). Samples were collected
early in a 5 ml vacutainer tube with EDTA, and they were centrifuged at 4 ◦C over 7 min at 3500 rpm.
Finally, samples were kept at −40 ◦C until analysis. A biochemical serum lipid profile (TC, HDL and
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LDL cholesterol, triglycerides, apolipoprotein A1, apolipoprotein B, and free fatty acids), and glucose
determinations were performed by an enzymatic-spectrophotometric assay using an Olympus AU
5400 apparatus (Izasa, CA, USA). C-reactive protein (CRP) concentrations were determined using a BNII
nephelometer (Siemens Healthcare Diagnostics GmbH, Eschborn, Germany). Tumor necrosis factor-α
(TNF-α) and interleukin 6 (IL-6) were determined using a Luminex®-100 (Luminex Corporation. Texas
City, TX, USA) multianalyte profiling system with commercially available immunoassay panels. Total
lipid peroxides in plasma were determined as an indicator of oxidative stress by using the thiobarbituric
acid reactive substances (TBARS) method21. The results were expressed as µmol MDAeq/mL. Data
were analyzed using the xPONENT v.3.1 software (Merck Millipore, Burlington, VT, USA) and were
determined using specific protocols of La Paz University Hospital.
2.6. Compliance and Adverse Events
Compliance was measured at the end of each experimental period using a specific questionnaire,
and a subject was considered compliant when he/she consumed the contents of ≥70% of the product.
Adverse events were recorded during the experimental periods. An adverse event was defined as
any unfavorable, unintended effect reported by a subject or observed by the investigator. All were
recorded along with the symptoms involved (nausea, vomiting, diarrhea, halitosis, and/or constipation).
No participants showed any signs of intolerance to the supplement of the study diets. Subjects were
informed of their right to withdraw from the study at any time.
2.7. Statistical Analysis
The sample size of 30 subjects in each group was calculated to provide 90% power at a 5%
level of significance by the power analysis (nQuery Advisor Release 2.0, Statistical Solutions, Boston,
MA, USA) based on LDL-C as a target effect size. The primary outcomes of the study were the
changes from baseline to week 12 in the TC, low density lipoprotein cholesterol, and high-density
lipoprotein cholesterol. Changes in triglycerides, free fatty acids, lipoproteins apoA-1 and apoB, fasting
glucose, fasting insulin, body mass index, waist circumference, and the percent of fat tissue and its
distribution assessed by android-to-gynoid fat percent ratio, as well as the total visceral adipose tissue,
inflammatory markers (CRP, IL-6, TNF-α, oxidized low-density lipoprotein (OxLDL), and fibrinogen),
calcium, phosphate, vitamin D, ghrelin, and leptin were considered as secondary outcomes. Baseline
features in the intervention and control group were compared by a t-test (continuous variables) or by a
chi-squared test (categorical variables). Changes in the primary and secondary outcomes from baseline
to week 12 were defined by the absolute difference of the value of a parameter in week 12 minus the
value at baseline. The statistical analysis of not normally distributed parameters were assessed by a
Mann–Whitney U non-parametric test. The 95% confidence intervals of the absolute difference of the
mean changes between the intervention and control groups were calculated by adjusted bootstrap
percentile method after a 1000-replication bootstrap. Statistical calculations were performed in R
(R Core Team (2013), Vienna, Austria).
3. Results
3.1. Recruitment and Study Population
Eighty possible patients were screened for enrolment in this study, but only sixty-eight met the
inclusion and exclusion criteria and were randomized. The participant flow diagram is shown in
Figure 1. Nine participants did not finish the study due to personal reasons, refusal to participate
further, or relocations. Thus, fifty-nine subjects finished the 12-wk intervention period (control group:
31 subjects; experimental group: 28 subjects); only their data were included in analysis.
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Figure 1. Flow chart describing the present trial.
3.2. Baseline Characteristics
The baseline characteristics of the fifty-nine subjects who completed the study were found to be
comparable between the two groups are described in Table 1. The treatment compliance was high,
and no differences were observed between groups (>85% of the scheduled doses consumed in the CG;
>87% in the EG; p < 0.374) (Table 1).
Table 1. Baseline characteristics and anthropometric parameters of the study participants before and
after the intervention.
Characteristic Week 0 Week 12 Week 12–Week 0
CG EG CG EG CG EG p–Value
Age (years) 47.60 ± 9.40 48.50 ± 7.80 - - - - -
Men (n) 8 6 - - - - -
Women (n) 23 22 - - - - -
Weight (kg) 85.6 ± 11.30 86.80 ± 15.80 82.18 ± 11.77 83.13 ± 15.75 −3.41 ± 3.13 −3.66 ± 2.46 0.865
BMI (kg/m2) 31.05 ± 3.30 30.74 ± 4.20 30.47 ± 3.69 30.54 ± 4.09 −1.12 ± 0.20 −0.93 ± 0.17 0.756
Waist circ. (cm) 105.0 ± 10.50 99.55 ± 10.60 96.29 ± 12.79 97.03 ± 11.09 −5.74 ± 6.63 −5.87 ± 3.18 0.889
BMD (g/cm2) 1.17 ± 0.12 1.16 ± 0.13 1.17 ± 0.12 1.16 ± 0.14 −0.004 ± 0.01 −0.002 ± 0.14 0.767
Lean mass (%) 45.23 ± 7.77 46.15 ± 9.72 44.75 ± 8.00 45.72 ± 9.84 −0.49 ± 1.24 −0.43 ± 1.21 0.723
Android fat (%) 51.62 ± 7.19 50.72 ± 7.14 48.83 ± 9.29 48.92 ± 7.82 −2.80 ± 2.99 −1.80 ± 2.44 0.436
Gynoid fat (%) 47.24 ± 7.53 47.22 ± 8.24 45.64 ± 8.22 45.20 ± 8.14 −1.60 ± 1.99 −2.02 ± 1.90 0.356
Total fat mass (%) 46.94 ± 5.87 46.27 ± 6.29 44.55 ± 6.87 43.11 ± 6.67 −1.79 ± 1.80 −1.72 ± 1.68 0.645
Systolic BP (mm Hg) 110.3 ± 14.00 110.9 ± 13.10 110.7 ± 10.09 105.64 ± 22.05 0.45 ± 9.41 −5.21 ± 21.35 0.123
Diastolic BP (mm Hg) 77.50 ± 10.70 76.50 ± 9.50 76.90 ± 8.53 75.07 ± 8.38 −0.61 ± 7.99 −1.46 ± 7.79 0.385
HR (rate per minute) 75.30 ± 10.50 77.70 ± 10.50 68.10 ± 11.97 75.71 ± 13.70 −7.23 ± 9.39 −1.96 ± 10.97 0.259
Data are expressed as the means ± SDs. Abbreviations: BMI: body mass index; Waist circ.: waist circumference;
BMD: bone mineral density; BP: blood pressure; and HR: heart rate.
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3.3. Dietetic and Anthropometric Variables
In general, the diets followed by the volunteers showed a similar intake of macro- and
micro-nutrients. No significant baseline differences in the basal diet were noted among the groups,
except for the weekly rations of legumes (p = 0.025) and water (p = 0.012), which were higher in the EG
compared to the CG. Instead, weekly rations of meat (p = 0.021) were higher in the CG. Regarding
the low number of adverse events reported, no conclusion towards a relationship with a specific
intervention could be drawn. There was no significant change in body weight in either treatment
group, nor in the BMIs after the 12 weeks of study (p > 0.05) (Table 1). Additionally, there were no
significant differences between treatments in all the parameters of the DXA analysis, which allowed us
to obtain accurate values of the variation of body composition (p > 0.05) (Table 1). Regarding the waist
circumference, no significant differences were found in the baseline GC and EG values (p > 0.05).
3.4. Blood Pressure and Biochemical Variables
On the other hand, at the end of the intervention period, both systolic and diastolic blood pressure
remained within normal values for the general population (120/80 mmHg). Though systolic blood
pressure decreased by −5.21 ± 21.35 mm Hg in the EG there were no significant differences among
groups, possibly due to intragroup differences, nor were there any significant differences at baseline or
after the intervention for 12 weeks (p > 0.05) (Table 1).
The subjects’ blood lipids and apolipoproteins concentrations before and after intervention are
shown in Table 2. At the end of the study, the level of TC increased significantly in the EG in comparison
to the CG (p > 0.05), despite no significant difference from baseline observed in either group. Even
though randomization, there was an imbalance between both groups in baseline HDL-C concentration
(p = 0.04), with lower baseline HDL-C levels in the EG. However, this result was corrected, and a
significant increase of HDL-C in favor of the EG occurred at the end of the intervention. The plasma
levels of ApoA1 and ApoB remained within the reference values for the study population throughout
the intervention period (Table 2). At the end of the intervention, no changes in ApoA1 levels (related
to HDL-C, the most abundant apolipoprotein in plasma, which contributed to a good cardiovascular
health [14]) were detected in any group. On the contrary, the plasma concentration of ApoB increased
in the EG by the end of the intervention period (Table 2).
Additionally, the increase of TC in the EG could have been related to the significant increase of
the HDL content in this group. Conversely, the consumption of cheese in both intervention groups
did not significantly affect LDL-C values, leading to a significant improvement in the LDL/HDL ratio,
a good lipid indicator of atherogenic risk along with the TC/HDL-C ratio (Table 3).
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Table 2. Blood lipids and apolipoproteins concentrations before and after intervention.
(mg/dL)
CG EG Week 12–Week 0
Week 0 Week 12 Week 0 Week 12 CG EG CI 95%
TC 201.80 ± 40.41 197.16 ± 36.95 195.39 ± 37.38 201.46 ± 38.81 −2 (−90; 43) 6.5 (−24; 50) 10.72 (0.37; 22.74) #
HDL-C 54.97 ± 16.47 * 53.97 ± 11.08 47.89 ± 8.00 * 52.00 ± 9.24 2 (−48; 12) 4.5 (−5; 16) 5.11 (1.96; 11.46) #
LDL-C 128.97 ± 31.34 125.61 ± 29.29 127.32 ± 32.45 129.71 ± 31.59 3 (−11; 16) 2.5 (−9; 31) 1.39 (−2.15; 5.92)
TAG 89.00 ± 42.24 87.81 ± 47.65 100.71 ± 34.33 99.50 ± 31.59 6 (−65; 75) 1 (−56; 53) −0.02 (−12.8; 14.62)
ApoA1 161.32 ± 26.62 153.94 ± 20.85 150.68 ± 16.30 152.14 ± 18.40 −1 (−28; 9.6) 0.3 (−9.8; 24) 2.74 (−0.3; 6.98)
ApoB 102.42 ± 21.45 101.65 ± 22.06 102.86 ± 23.33 108.00 ± 26.20 −2* (−19; 27) 3.5* (−20; 34) 5.92 (0.81; 11.77)
Glucose 93.06 ± 8.08 95.39 ± 8.49 90.82 ± 9.40 94.54 ± 7.54 2.32 (70.04; 94.06) 3.71 (67.05; 95.04) 0.05 (–0.1; 0.19)
Data are expressed as the means ± SDs. Statistical analysis was assessed by Mann–Whitney U test. * Significant difference between groups at week 0 p < 0.05. # Significant difference
between groups at the end of the intervention period (week 0–week 12) p < 0.05. Abbreviations: TC: total cholesterol; HDL-C high-density lipoprotein cholesterol; LDL-C low-density
lipoprotein cholesterol; and TAG triglycerides.
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Table 3. Values of total cholesterol/high-density lipoprotein (TC/HDL), low-density lipoprotein
(LDL)/HDL and apolipoprotein B/apolipoprotein A1 (ApoB/ApoA1) ratios before and after
the intervention.
Ratio CG (n = 31) EG (n = 28)
Week 0 Week 12 Week 0 Week 12
TC/HDL-C 3.67 ± 2.5 3.67 ± 3.3 4.06 ± 4.6 3.87 ± 4.6
LDL-C/HDL-C 1.71 ± 1.9 1.72 ± 2.6 1.91 ± 4.0 1.79 ± 3.4 *
ApoB/ApoA1 0.63 ± 0.8 0.66 ± 1.1 0.68 ± 1.43 0.71 ± 1.42
Data are presented as mean ± s.d. * Significant difference between groups before and after the intervention p < 0.05.
Abbreviations: TC: total cholesterol; HDL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein
cholesterol; and TAG: triglycerides.
3.5. Inflammation Variables
Systemic inflammation (TNF-α, IL-6, CRP, and others) is described in Table 4. At baseline, there
was no difference between groups in any of these characteristics. After intervention, there was a
significant decrease in CRP in the EG by 36%, taking into account the intragroup variation.
Plasma calcium and phosphorous remained within the ranges of normality described throughout
the intervention period (Table 5). At baseline, there was no difference between groups in the plasma
levels of vitamin D, but there were lower than the reference range for the study population (20–40 ng/mL)
in both the CG and the EG, maybe linked to overweight and obesity status [15]. In contrast, at the
end of the intervention period, vitamin D plasma levels were found within values considered in the
reference range for the study population [16]. There was also no significant change in ghrelin and
leptin after the intervention in either group.
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Table 4. Inflammatory biomarker concentration before and after the intervention.
CG EG Week 12–Week 0 CI 95%
Week 0 Week 12 Week 0 Week 12 CG EG
CRP (mg/L) 2.67 ± 4.36 2.98 ± 7.62 2.95 ± 6.06 1.02 ± 6.33 0.03 (−18.12; 32.1) −0.76 (−12.34; 3.38) –10.72 (0.37; 22.74) #
TNF-α (pg/mL) 3.88 ± 1.45 4.47 ± 1.43 4.51 ± 1.57 4.85 ± 1.71 0.5 (−0.8; 18.3) 0.75 (−1.2; 2.5) −0.46 (−246; 0.28)
IL-6 (pg/mL) 2.60 ± 2.37 3.70 ± 2.25 2.70 ± 1.53 3.65 ± 1.60 1.2 (−1.7; 3.2) 0.95 (−2; 5.2) −0.12 (−0.82; 0.6)
Fibrinogen (mg/dL) 397 ± 102.82 413 ± 97.33 419 ± 124.14 346 ± 129.64 −13 (−333;425) −17 (−202; 106) −26.88 (−81.27; 22.96)
OxLDL (ng/mL) 72.71 ± 238.10 80.53 ± 245.14 135.09 ± 229.32 113.47 ± 218.01 0.01 (−164.2; 654.9) −0.31 (−250.9; 90.4) −13.3 (−87.2; 16.9)
FFA (mM) 0.28 ± 0.17 0.25 ± 0.08 0.28 ± 0.11 0.23 ± 0.10 −0.01 (−0.47; 0.21) −0.06 (−0.41; 0.2) −0.03 (−0.09; 0.04)
Data are expressed as the means ± SDs. Statistical analysis was assessed by Mann-Whitney U test. Significant difference between groups at week 0 p < 0.05. # Significant difference between
groups at the end of the intervention period (week 0–week 12) p < 0.05. Abbreviations: CRP: high-sensitivity C reactive protein; TNF-α: tumor necrosis alpha factor; IL-6: interleukin 6;
oxLDL: oxidized LDL; and FFA: free fatty acids.
Table 5. Mineral and hormone concentrations before and after the intervention.
CG EG Week12–Week 0 CI 95%
Week 0 Week 12 Week 0 Week 12 CG EG
Vitamin D (ng/mL) 14.26 ± 6.15 21.89 ± 6.94 13.95 ± 6.06 22.5 ± 6.33 7 (1; 23) 8 (0; 17) 0.39 (−2.2; 2.26)
Calcium (mg/dL) 9.16 ± 0.38 9.24 ± 0.30 9.16 ± 0.32 9.30 ± 0.35 0.1 (−0.6; 0.7) 0.15 (−0.3; 0.9) 0.05 (−0.1; 0.19)
Phosphorous (mg/dL) 3.35 ± 0.39 3.41 ± 0.52 3.46 ± 0.59 3.32 ± 0.47 0.1 (−0.8; 0.8) −0.1 (−1.4; 0.8) −0.19 (−0.41; 0.02)
Ghrelin (pg/mL) 9.9 ± 13.75 10 ± 14.42 8.45 ± 19.62 8.10 ± 20.69 0.6 (−35.7; 40.3) 0.05 (−41.8; 39.2) −0.37 (−7.72; 6.78)
Leptin (pg/mL) 14.14 ± 10.74 11.01 ± 10.00 14.80 ± 10.80 11.15 ± 10.50 −1.8 (−23.03; 13.1) −2.7 (−9.5; 2.5) −0.12 (−0.82; 0.6)
Data are presented as mean ± SDs.
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4. Discussion
This study was designed to evaluate the combined effect of a enriched cheese with a balanced
hypocaloric diet and physical activity in overweight and obese subjects on cardiovascular risk factors.
This diet enriched with n-3 PUFA and CLA did not significantly modify the body composition of
either group. The lack of significant differences is in agreement with recent clinical trials in which
the consumption of cheese naturally enriched with PUFA did not significantly modify the body
composition of both healthy volunteers and subjects with altered lipid profiles [4,17]. Though the
difference was not significant between both groups (p > 0.05), the reduction of the waist circumference
in both intervention groups could be related to the good efficacy of the nutritional intervention and the
guidelines for physical activity carried out in both intervention groups, thus decreasing the metabolic
risk in relation to waist circumference specified by the WHO (>88 cm in women and >102 cm in men)
(Table 1) [18]. These results are in accordance with those obtained in a recent clinical trial in which
cheese consumption did not significantly modify anthropometric parameters related to metabolic risk
among the different study groups [19]. Lastly, the slight non-significant decrease in heart rate observed
at the end of the study in both groups may have been a consequence of weight loss, thus improving an
important cardiovascular risk (CVR) factor [20] (Table 1). These results are in accordance with those
obtained in a recent clinical trial in which a similar intervention period of 12 weeks has been previously
shown to induce significant weight loss [21].
The DXA analysis revealed a baseline value of TFM that exceeded the typical values in overweight
people (BMI 25–30 kg/m2) in both intervention groups. Though no significant differences were obtained
between treatments, probably due to the low-calorie diet received by all volunteers (p > 0.05), at the
end of the intervention, both groups had a slightly decreased TFM, AF and GF (Table 1). Recent studies
have shown that weight loss and/or muscle mass could lead to a loss of BMD, thus highlighting the
importance of a good dietary strategy in the management of overweight and obesity and avoiding the
loss of muscle mass by performing regular physical exercise [22]. Consequently, the results showed the
good follow-up of the recommendations for the daily performance of physical activity by all volunteers.
Regarding the increase in TC (the sum of HDL-C and LDL-C) in the EG, TC provides limited
information about cardiovascular risk, and it is not useful for diagnosing metabolic syndrome [23]
because it cannot be associated with a circulating increase in atherogenic lipoprotein concentration [24].
However, the significant increase in HDL-C in the EG after the intervention period was in line with
another clinical trial in which hypercholesterolemic volunteers consumed PUFA-enriched yogurt for
10 weeks [25]. Furthermore, de Goede et al. (2015) in a recent review, concluded that the cheese intake
as compared to butter might have beneficial effects on certain plasma lipids that are directly related to
the antiatherogenic properties of CLA. Though the differences in the LDL-C/HDL-C ratio between
the CG and the EG were not statistically significant (p > 0.05), the results showed a slight decrease in
the atherogenic risk only in the EG at the end of the intervention. These results were in line with a
recent study that evaluated the effect of the consumption of a LC n-3-PUFA-enriched cheese on the
lipid profile in hypercholesterolemic adults [26]. In the study, no significant differences were found
between both groups on plasma TAG (Table 2). This approach is in line with a recent review and
meta-analysis where de Goede et al. (2015) concluded that cheese consumption has no effect on TAG
levels in humans, and this effect could also be dependent on the intervention time [27]. Furthermore,
a recent large review of nine RCT suggests that CLA did not significantly affect TC, TAG, or LDL-C
contents [28]. On the contrary, Carrero et al. (2007) [29] supplemented hyperlipidemic volunteers with
a milk product containing EPA plus DHA, and they observed a significant reduction in TAG and TC
after eight weeks. In terms of increasing the plasma ApoB concentration in the EG, previous studies
have reported significant changes in plasma ApoB concentration or even increases when prescribing
therapies with LC n-3-PUFA, underscoring the importance of treatment duration to attain consistent
results [30]. However, ApoB plasma levels in both groups were in the reference range of Apo B levels
in adults, and there were no significant changes in plasma LDL-C levels, so this increase in ApoB
levels cannot be considered an increase of cardiovascular risk [31]. The ApoB/ApoA1 ratio reflects
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the balance between two processes: the transport of cholesterol to peripheral tissues and the reverse
transport to the liver. Due to the results obtained for the ApoA1 and ApoB values in both intervention
groups, significant differences between the CG and the EG in the ApoB/ApoA1 ratio between before
and after the intervention were not observed, but this ratio slightly increased at the end of the clinical
trial in both groups.
Weight loss is associated with reduced levels of pro-inflammatory cytokines responsible for
inflammation, such as TNF-α and IL-6 [32]. Though recent studies have shown an increase in TNF-α
and IL-6 levels due to the state of inflammation related to overweight and obesity [15], the consumption
of 60 g/day of cheese, following a balanced and hypocaloric diet, kept these levels stable at the end of
the intervention period (Table 4). These results were in line with those reported by Dawczynski et al.
(2013) [7], where the consumption of PUFA-enriched yogurt did not significantly modify the values
of inflammation markers studied in overweight and obese volunteers. Similarly, in our study at the
end of 12 weeks of supplementation, there was no significant effect in plasma OxLDL, fibrinogen, and
FFA compared with the control group, probably due to the wide variability among the volunteers in
each group. These results were in line with those obtained by Joseph et al. (2011) [5] in an eight-week
crossover clinical trial in which dietary supplementation with CLA-enriched oil did not modify plasma
OxLDL values in overweight and hyperlipidemic subjects. Additionally, the plasma CRP concentration
increases its levels in response to generalized inflammation, as in the case of overweight and obese
individuals [33]. At the end of the intervention, the plasma CRP concentration increased by 37% in the
CG, whereas this value, taking into account the intragroup variation, significantly decreased in the EG
by 36%. This significant decrease in the plasma CRP concentration only in the EG did not coincide with
previous studies in which the consumption of enriched dairy products in FA n-3 did not significantly
modify the plasma levels of pro-inflammatory cytokines [33]. The lack of significant changes in levels
of CRP has been also attributed to the duration of the intervention. Additionally, the reduction in
CRP levels could be directly related to weight loss, decreasing 0.13 mg/dL CRP per kg of weight
lost [33]. The consumption of FA n-3 increases their concentration in blood, cells, and tissues, and it
alters the physical properties of cell membranes and the function of membrane proteins. FA n-3 is
incorporated into cell membranes in competition with n-6 FA and AA. Considering that the replacement
of n-6 FA with n-3 FA in membranes of the immune active cells may induces leucocytes to produce
pro-inflammatory processes and lead to the reduced formation of pro-inflammatory compounds, the
significant changes of plasma CRP levels in overweight and obese subjects only in the EG could
have been due to the synergistic effect among the anti-inflammatory effect of the consumption of
dietary FA n-3 and CLA, weight loss, and the consumption of a balanced diet, together with regular
physical activity.
Calcium and phosphorus interact in numerous processes of the organism. Blood calcium values
considered normal for a studied population are usually between 8 and 10.5 mg/dL, as well as between
2.4 and 4.5 mg/dL for phosphorus. For the population under study, the normal blood calcium and
phosphorus values ranged between 8 and 10.5 mg/dL and between 2.4 and 4.5 mg/dL, respectively.
In regards to vitamin D (which regulates mineral homeostasis, protects the integrity of the skeleton,
and modulates cell growth and differentiation in a wide variety of tissues [34]), although there were no
significant differences between both groups, the baseline levels of vitamin D in both the GC and the
EG were lower than those considered normal for the study population (20–40 ng/mL), and this may be
linked to overweight and obesity status [35]. On the other hand, hormonal regulators of satiety, such
as ghrelin and leptin, are also related to body weight. Though no significant changes were seen in
terms of intervention time and treatment group at the end of the clinical trial, an intragroup analysis
revealed a slight decrease in leptin levels in both the GC and the EG. These results were expected after
the hypocaloric diet and the consequent weight loss in both groups, as well as changes in the blood
lipid profile [36].
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5. Conclusions
Overall, the consumption of 60 g/day of cheese (both control and enriched), within the context of
a balanced hypocaloric diet and recommendations for physical activity, was effective for the reduction
of body weight, BMI and waist circumference in both the CG and the EG. Additionally, the healthy
habits carried out by all subjects resulted in a slight decrease in heart rate, as well as maintenance of
the BMD, resulting in a decrease in CVR.
On the other hand, the significant increase of HDL and the significant decrease in blood levels
of CRP in the EG improved the plasma lipid profile and the inflammatory status, thus producing a
decrease in the atherogenic risk. Therefore, the consumption of this PUFA n-3 and CLA naturally
enriched goat cheese could have a potential role as a high nutritional value food to improve the state
of health.
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